Rosetta Medtech MCP

A second MCP server on the same audited dataset, built for organisations rather than patients. It answers questions such as: which EU and national rules apply to an AI mammography tool or a molecular pathology panel in Romania, the Netherlands and Germany; where national rules go beyond EU law; which EU-recommended services are missing in a country; and which cross-border route fits a diagnostic claim.

MVP, provided as is, non-commercial. No fees are charged, no service level is offered, and results are not legal, regulatory or medical advice. See terms of use.

Who it is for

Larger medtech and diagnostics companies

Market-access maps per country and step: MDR and IVDR, radiation protection, HTA, EHDS, plus the national extra layers (for example the Dutch screening permit regime or German genetic testing law). Change alerts through the existing webhook listener.

Startups

Where EU-recommended care is not yet implemented nationally (unmet demand), which peer country already does it, and which national rule to plan for before a pilot.

Insurers and claims handlers

Faster checks of cross-border diagnostic claims: Directive 2011/24/EU or S2 route, prior authorisation likelihood, required documents and national rules that commonly make a claim fail.

Researchers

Procedure crosswalks with a citable id, so patient pathways can be compared across countries in published studies.

Connect

Endpoint (Streamable HTTP, JSON responses, read-only): /mcp/medtech. The patient and academic server stays at /mcp.


  

Tools

ToolWhat it returns
Loading…

The same answers over REST

QuestionEndpoint
Market access for a step/api/market-access?concept=oncology.dx.biomarker
Cross-border claim check/api/claim-check?concept=oncology.dx.imaging.pet_ct&from=RO&to=DE
Two-way gap audit/api/gaps?jurisdiction=NL&direction=national_to_eu
Research crosswalk/api/translate?concept=oncology.dx.screening&from=RO&to=NL
Knowledge graph/api/kg.jsonld, /api/kg.ttl
Service terms/api/service

What you can rely on

Pricing

A pricing proposal is in preparation for three groups: larger companies, startups and insurers (subscription and usage-based options). Until it is published, the MVP is free to use under the terms, and no commercial service is offered.

Interested in early access, a pilot or research collaboration? Contact: see the terms page.